Animal Pharm’s panel of independent judges selected Zomedica for its product pipeline, equity funding, TSXV listing, and strategic personnel additions in 2016. This year’s awards featured 11 category winners that highlight the upsurge in innovation for companion animals that occurred in 2016. LEARN MORE>>
Zomedica Pharmaceuticals Corp. has started talks with the U.S. Food and Drug Administration on the company’s third proposed veterinary product: an oral suspension formulated for the treatment of canine diarrhea.
The Ann Arbor startup, which is in the early stages of developing drugs for cats, dogs and horses, announced last week it has finished raising the first segment of a private offering of $15 million Canadian, or the equivalent of about $11.7 million U.S. The company is part of a growing array of startups seeking to develop drugs tailored to …
Last year, Zomedica was formed to bring products for unmet needs into the companion animal market. The company’s product strategy was built around its core of two doctors of veterinary medicine and their experiences in the field. Animal Pharm editor Joseph Harvey spoke to one of these executives to find out more about the industry’s latest pet-focused start-up.
Zomedica Pharmaceuticals Corp. has entered the companion animal health space with an aim to take a sizeable market slice by targeting the unmet needs of clinical veterinarians.